The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians

Conclusion The final document highlights that no proof of difference among drugs exists, that evidence on final endpoints (and particularly on mortality) should be strengthened and that actions regarding risk factors, appropriate diagnosis, patient staging and adherence to therapy are particularly important for a better clinical management.
Source: Multidisciplinary Respiratory Medicine - Category: Respiratory Medicine Source Type: research